125 related articles for article (PubMed ID: 8798759)
1. Degradation of topoisomerase IIalpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system.
Nakajima T; Morita K; Ohi N; Arai T; Nozaki N; Kikuchi A; Osaka F; Yamao F; Oda K
J Biol Chem; 1996 Oct; 271(40):24842-9. PubMed ID: 8798759
[TBL] [Abstract][Full Text] [Related]
2. [Degradation of topoisomerase II alpha precedes nuclei degeneration during adenovirus E1A-induced apoptosis and is mediated by the activation of the ubiquitin dependent proteolysis system].
Nakajima T
Nihon Rinsho; 1996 Jul; 54(7):1828-35. PubMed ID: 8741674
[TBL] [Abstract][Full Text] [Related]
3. Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis.
Nakajima T; Kimura M; Kuroda K; Tanaka M; Kikuchi A; Seino H; Yamao F; Oda K
Biochem Biophys Res Commun; 1997 Oct; 239(3):823-9. PubMed ID: 9367853
[TBL] [Abstract][Full Text] [Related]
4. Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway.
Nakajima T; Morita K; Tsunoda H; Imajoh-Ohmi S; Tanaka H; Yasuda H; Oda K
J Biol Chem; 1998 Aug; 273(32):20036-45. PubMed ID: 9685342
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus E1A-induced apoptosis elicits a steep decrease in the topoisomerase II alpha level during the latent phase.
Nakajima T; Ohi N; Arai T; Nozaki N; Kikuchi A; Oda K
Oncogene; 1995 Feb; 10(4):651-62. PubMed ID: 7862442
[TBL] [Abstract][Full Text] [Related]
6. Role of proteasomal degradation in the cell cycle-dependent regulation of DNA topoisomerase IIalpha expression.
Salmena L; Lam V; McPherson JP; Goldenberg GJ
Biochem Pharmacol; 2001 Apr; 61(7):795-802. PubMed ID: 11274964
[TBL] [Abstract][Full Text] [Related]
7. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
8. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
Kwon Y; Shin BS; Chung IK
J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
[TBL] [Abstract][Full Text] [Related]
9. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
10. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.
Li B; Dou QP
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):3850-5. PubMed ID: 10725400
[TBL] [Abstract][Full Text] [Related]
11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
12. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall NR; Mohammad RM; Reddy KB; Al-Katib AM
Int J Mol Med; 2000 Feb; 5(2):165-71. PubMed ID: 10639596
[TBL] [Abstract][Full Text] [Related]
13. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
14. Hypophosphorylation of topoisomerase IIalpha in etoposide (VP-16)-resistant human carcinoma cell lines associated with carboxy-terminal truncation.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):799-805. PubMed ID: 11473732
[TBL] [Abstract][Full Text] [Related]
15. The SUMO pathway is required for selective degradation of DNA topoisomerase IIbeta induced by a catalytic inhibitor ICRF-193(1).
Isik S; Sano K; Tsutsui K; Seki M; Enomoto T; Saitoh H; Tsutsui K
FEBS Lett; 2003 Jul; 546(2-3):374-8. PubMed ID: 12832072
[TBL] [Abstract][Full Text] [Related]
16. Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIalpha and beta in various human cancer cell lines.
Hochhauser D; Valkov NI; Gump JL; Wei I; O'Hare C; Hartley J; Fan J; Bertino JR; Banerjee D; Sullivan DM
J Cell Biochem; 1999 Nov; 75(2):245-57. PubMed ID: 10502297
[TBL] [Abstract][Full Text] [Related]
17. Active DNA topoisomerase IIalpha is a component of the salt-stable centrosome core.
Barthelmes HU; Grue P; Feineis S; Straub T; Boege F
J Biol Chem; 2000 Dec; 275(49):38823-30. PubMed ID: 11006289
[TBL] [Abstract][Full Text] [Related]
18. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
19. Demonstration that a human 26S proteolytic complex consists of a proteasome and multiple associated protein components and hydrolyzes ATP and ubiquitin-ligated proteins by closely linked mechanisms.
Kanayama HO; Tamura T; Ugai S; Kagawa S; Tanahashi N; Yoshimura T; Tanaka K; Ichihara A
Eur J Biochem; 1992 Jun; 206(2):567-78. PubMed ID: 1317798
[TBL] [Abstract][Full Text] [Related]
20. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
